© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Montelukast Sodium stands as a raw material in the pharmaceutical world, recognized for its role in managing symptoms tied to asthma and allergic rhinitis. Appearance reveals a solid, often encountered as off-white to yellowish flakes, crystalline powder, or granulated pearls, depending on batch processing conditions and handling. Commonly, the substance is neither oily nor volatile under room temperature, delivering convenience in storage and transportation.
Chemically, Montelukast Sodium is known by the molecular formula C35H35ClNNaO3S with a molecular weight of 608.17 g/mol. The molecular structure consists of a quinoline core, multi-ring system, one sodium ion balancing the negative charge, a sulfonyl group, and a distinctive chlorophenyl chain. Such a layout enhances solubility in water, which facilitates precise dosing during drug formulation. Density hovers around 1.05 g/cm³ to 1.15 g/cm³, suggesting that even at moderate volumes, powders and crystals compact easily without unnecessary bulk, supporting production line efficiency. The raw material usually dissolves in methanol, dimethyl sulfoxide (DMSO), and only slightly in water unless formulated as a solution. Crystallinity stands out: this property offers manufacturers predictability in batch-to-batch quality because crystalline forms demonstrate reliable flow and mixing behavior. Specific rotation and melting point parameters form part of regulatory documentation, enabling traceability and authenticity assurance against counterfeits.
Users can encounter Montelukast Sodium as a fine powder, large or small crystalline flakes, compressed pearls, or even as a solution. Pharmaceutical plants lean toward powders or flakes due to rapid dissolution, precise mass measurement, and dust control for occupational safety. The solid state preserves stability during shipping and long-term storage, with sealed containers guarding against hydrolysis and oxidation. Granule sizing affects dissolution and absorption rates, which links directly to how the final medication functions inside the patient’s body. No strong odor emits from the powder, supporting cleanroom and GMP standards. Flake and crystal forms often receive preference where a highly defined physical state is necessary for quality assurance testing or regulatory records.
Trade and logistics categorize Montelukast Sodium under HS Code 2935009090. This classification ties to the international harmonized system for chemicals used as pharmaceutical raw materials. Global shipments sail under this code with careful labeling to meet customs and regulatory scrutiny. Material safety data sheets reference this identifier, and buyers rely on it when sourcing high-purity pharmaceutical inputs from licensed suppliers. Policing authenticity and documentation at this code level forms a critical defense against illicit drug trade and counterfeit interventions worldwide.
Handling Montelukast Sodium demands care but not extraordinary safety measures beyond standard laboratory practices. Powders and crystals may pose inhalation hazards if airborne particles accumulate, triggering mild respiratory or eye irritation in unprotected workers. Gloves, goggles, and dust masks form basic precautions during mass transfers and weighing. Spillages clean up with vacuum or damp wiping to keep fine particles from lingering in the work area. As a non-flammable solid, fire risk stays low under ordinary working and storage conditions. Direct ingestion, exposure to open wounds, or unauthorized use must be avoided—this chemical acts as a pharmacologically active compound only under careful prescription and supervision.
Long shelf life arises from proper sealing, protection from moisture, and low UV exposure. Bulk containers often utilize high-density polyethylene or stainless steel drums with desiccants inside. Storage at room temperature suffices, yet extreme humidity or temperature swings threaten structural integrity, color, or chemical purity. Routine laboratory checks trace purity, melting point, particle size distribution, residual solvents, and water content. Deviations from expected density or appearance flag possible contamination or mishandling—a critical checkpoint before proceeding to formulation. This robust attention to material quality not only underpins regulatory compliance but ultimately shields patient safety downstream.
Montelukast Sodium’s pharmacological potency means even trace contamination with dust or residues in manufacturing environments could present health hazards. Regular surface monitoring, batch-specific hazard communication, and operator training go hand-in-hand to maintain safe use. Waste disposal depends on local environmental regulations but generally requires containment in sealed, labeled chemical waste streams. Clean work habits, vigilant quality checks, and timely documentation let teams prevent mix-ups and accidental exposures.
As the pharmaceutical sector grows, demand for high-quality Montelukast Sodium sourced through transparent, auditable supply chains keeps rising. Modernizing storage, embracing automated powder handling, and deploying advanced analytical tools enhance both workplace safety and batch reliability. International collaboration around classification, hazard labeling, and traceability extends protection to workers and patients alike. Prioritizing staff training and facility upgrades makes the daily handling of chemically active agents like Montelukast Sodium both efficient and safe, which ultimately raises standards across the entire supply chain—from raw material to the medicines delivered at pharmacy counters.
